# Guangdong Jianke Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/guangdong-jianke-pharmaceutical-co

- Industry: Internet
- Headquarters: Dongguan, China
- Website: www.jianke.com
- Total disclosed funding: $285M
- Latest round: Series C (May 20, 2020)
- Investors on record: 5

## About

Established in 2006 and based in Beijing, China, Guangdong Jianke Pharmaceutical Co., Ltd. is a medical technology company that provides Internet chronic disease management services. In May 2020, the firm raised USD 5 million in series C funding. In June 2022, it established the Chronic Liver Disease Health Management Center. In July 2024, the company was listed on the Hong Kong Stock Exchange. Its stock code is 06086.

The company's main product is an online pharmaceutical e-commerce platform. The medical online e-commerce platform sells medicines, health products, weight loss and skin care products, maternal and child products, etc. The company also provides one-on-one health consultation and medication guidance services.

The company’s revenue is generated by providing pharmaceutical products and pharmaceutical services.

In the future, the company will expand the market and recruit talents.

## Funding rounds

- Series C, May 20, 2020, $5M — HBM Partners
- Series B, Sep 5, 2018, $130M — HBM Partners, GTJA Investment Group, Crescent Point
- Series A, May 15, 2017, $50M — YungPark Capital, Volcanics Venture
- Series A, Jan 27, 2016, $100M — Crescent Point

## Investors

- Crescent Point (https://capitalatlas.ai/funds/crescent-point) — Series A, Series B
- YungPark Capital — Series A
- Volcanics Venture (https://capitalatlas.ai/funds/volcanics-venture) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series B